Frank L. Meyskens Jr.

Frank L. Meyskens Jr.'s AcademicInfluence.com Rankings

Philosophy

#4988

World Rank

#7683

Historical Rank

#1365

USA Rank

Logic

#2340

World Rank

#3314

Historical Rank

#567

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Frank L. Meyskens Jr. Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Frank L. Meyskens Jr. is the former Daniel G. Aldrich chair and director of the Chao Family Comprehensive Cancer Center; currently professor of medicine at the University of California, Irvine. Biography Meyskens received an MD from the University of California, San Francisco in 1972. At UC Irvine Meyskens holds appointments in cancer biology, epidemiology, public health, and pharmacological sciences.

(See a Problem?)

Frank L. Meyskens Jr.'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. (1996) (3479)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2009) (2033)
Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. (1996) (1209)
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2011) (999)
Polyamines and cancer: old molecules, new understanding (2004) (979)
Reactive Oxygen Species: A Breath of Life or Death? (2007) (839)
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. (2009) (673)
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial (2008) (460)
Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma (1992) (435)
Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia (2011) (433)
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. (2015) (424)
Rationale and strategies for chemoprevention of cancer in humans. (1987) (399)
The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. (2004) (386)
Quality of life end points in cancer clinical trials: review and recommendations. (1989) (367)
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. (1998) (365)
Prevention and early detection of prostate cancer. (2014) (357)
Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia (2002) (339)
Development of difluoromethylornithine (DFMO) as a chemoprevention agent. (1999) (333)
Retinoids as preventive and therapeutic anticancer agents (Part I). (1987) (333)
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. (1994) (289)
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. (2014) (289)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
Estimates of benefits and harms of prophylactic use of aspirin in the general population (2014) (270)
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. (2002) (234)
Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. (2004) (231)
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. (2014) (231)
Redox regulation in human melanocytes and melanoma. (2001) (215)
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. (2002) (174)
Response of oral leukoplakia to beta-carotene. (1990) (174)
Surviving adult cancers. Part 2: Psychosocial implications. (1989) (174)
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. (2013) (170)
Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. (1992) (168)
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. (1998) (165)
Retinoids as preventive and therapeutic anticancer agents (Part II). (1987) (148)
Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. (2005) (144)
Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. (2000) (136)
Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor (2005) (134)
Diet and Cancer: The Disconnect Between Epidemiology and Randomized Clinical Trials (2005) (130)
Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. (1998) (130)
Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. (2008) (128)
Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. (1987) (128)
Disulfiram induces apoptosis in human melanoma cells: a redox-related process. (2002) (128)
Inhibition of human melanoma colony formation by retinoids. (1979) (125)
Melanoma Epidemiology and Prevention. (2016) (122)
Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. (2000) (117)
Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. (2001) (115)
Chromosome 6q involvement in human malignant melanoma. (1983) (114)
Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. (1994) (110)
TOPICAL VITAMIN-A-ACID THERAPY FOR CUTANEOUS METASTATIC MELANOMA (1980) (109)
TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (MYCOSIS FUNGOIDES) WITH 13-CIS-RETINOIC ACID (1983) (108)
Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma. (1989) (106)
Surviving adult cancers. Part 1: Physiologic effects. (1989) (105)
End-of-Life care: guidelines for patient-centered communication. (2008) (105)
Activation of nuclear factor-kappa B in human metastatic melanomacells and the effect of oxidative stress. (1999) (103)
An Educational Program to Increase Cervical and Breast Cancer Screening in Hispanic Women: A Southwest Oncology Group Study (2005) (102)
Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. (1980) (102)
Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. (1990) (101)
Molecular mechanisms of flavonoids in melanin synthesis and the potential for the prevention and treatment of melanoma. (2016) (99)
Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. (1982) (98)
MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. (2009) (95)
Adenosine metabolism in human erythrocytes. (1971) (95)
Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial (2014) (91)
Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. (2004) (91)
Updates of reactive oxygen species in melanoma etiology and progression. (2014) (91)
Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. (1995) (89)
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy (2017) (89)
NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. (2012) (88)
When your favorite patient relapses: physician grief and well-being in the practice of oncology. (2003) (83)
Human Tumor Stem-Cell Assay (1983) (83)
Diagnosis of prostate cancer using differentially expressed genes in stroma. (2010) (83)
Beta-carotene produces sustained remissions in patients with oral leukoplakia: results of a multicenter prospective trial. (1999) (81)
Clinical correlations of in vitro drug sensitivity. (1980) (80)
Cancer Prevention: Obstacles, Challenges and the Road Ahead. (2016) (79)
New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. (1981) (78)
The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial (2008) (77)
A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. (1983) (76)
Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. (2003) (75)
Combination Chemoprevention for Colon Cancer Targeting Polyamine Synthesis and Inflammation (2009) (75)
Development of a polyamine database for assessing dietary intake. (2007) (74)
Etiologic Pathogenesis of Melanoma (2004) (73)
Coming of age--the chemoprevention of cancer. (1990) (73)
Phase II trial of beta-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. (1986) (72)
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. (2015) (72)
RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. (2001) (71)
13-Cis-retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer. (1985) (69)
Estimates of benefits and harms of prophylactic use of aspirin in the general population. (2015) (68)
Clinical correlations of drug sensitivity in the human tumor stem cell assay. (1980) (66)
Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2014) (65)
Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. (1984) (65)
Modulation and mediation of cancer by vitamins (1983) (65)
Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. (2014) (64)
Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. (1990) (64)
Pharmacokinetics of n‐4‐hydroxyphenyl‐retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients (1989) (64)
Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas (2009) (63)
Oxidative stress and antioxidants in the pathophysiology of malignant melanoma (2018) (63)
Cutaneous malignant melanoma (arizona cancer center experience). I. Natural history and prognostic factors influencing survival in patients with stage i disease (1988) (62)
Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas. (1991) (62)
Melanosomal Damage in Normal Human Melanocytes Induced by UVB and Metal Uptake—A Basis for the Pro‐oxidant State of Melanoma † (2008) (61)
Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. (1982) (61)
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. (2018) (58)
Development of the Bowman‐Birk inhibitor for oral cancer chemoprevention and analysis of neu immunohistochemical staining intensity with Bowman‐Birk inhibitor concentrate treatment (2003) (58)
Endocrine responsiveness in human melanocytes and melanoma cells in culture. (1981) (58)
Luminol-enhanced chemiluminescent response of human melanocytes and melanoma cells to hydrogen peroxide stress. (1997) (58)
Quantitation of drug sensitivity by human metastatic melanoma colony-forming units. (1981) (56)
The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. (1991) (55)
Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial (2013) (55)
HPV infection and number of lifetime sexual partners are strong predictors for ‘natural’ regression of CIN 2 and 3 (2003) (55)
Two-photon excited fluorescence lifetime imaging and spectroscopy of melanins in vitro and in vivo (2012) (54)
Oral isotretinoin therapy. Use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas. (1984) (53)
Inhibition of human malignant melanoma colony-forming cells in vitro by prostaglandin A1. (1983) (53)
Effect of oral isotretinoin on dysplastic nevi. (1989) (53)
Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure (2017) (52)
Role of topical tretinoin in melanoma and dysplastic nevi. (1986) (52)
Method for measurement of self-renewal capacity of clonogenic cells from biopsies of metastatic human malignant melanoma. (1982) (51)
Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. (2013) (50)
Prevention of cervical intraepithelial neoplasia and cervical cancer. (1995) (50)
Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas (2013) (49)
Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic (2011) (48)
A Randomized, Double Blind, Phase III Trial Using Oral β-Carotene Supplementation for Women with High-Grade Cervical Intraepithelial Neoplasia (2001) (48)
Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. (1985) (47)
Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. (1992) (47)
Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention (2007) (47)
Effect of 13‐cis‐retinoic acid and 4‐hydroxyphenyl‐all‐trans‐retinamide on human tumor colony formation in soft agar (1983) (46)
Diet and melanoma in a case-control study. (2005) (46)
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (46)
Alterations in Activating Protein 1 Composition Correlate with Phenotypic Differentiation Changes Induced by Resveratrol in Human Melanoma (2005) (46)
Biochemical studies of cytokinetic changes during tumor growth. (1970) (46)
Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. (1982) (46)
Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. (2010) (46)
Results of the use of vitamin A and retinoids in cutaneous malignancies. (1989) (44)
Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells. (2007) (44)
A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important (2013) (43)
Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease (1989) (43)
In vitro clonal assay for human metastatic melanoma cells. (1981) (43)
African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. (2001) (43)
Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers. (1996) (43)
Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. (2001) (42)
Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. (2004) (42)
New perspectives on melanoma pathogenesis and chemoprevention. (2007) (41)
Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea. (2002) (41)
Human melanoma colony formation in soft agar. (1980) (40)
The role of orchiectomy in the management of advanced male breast cancer (1976) (40)
Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer (1995) (38)
Nonsurgical Treatments for Skin Cancer: Retinoids and α‐Interferon (1988) (38)
Vitamin A: evidence for its preventive role in human cancer. (1983) (38)
Characterizing 18 Years of the Death With Dignity Act in Oregon (2017) (38)
Phase II study of Fenretinide (N-[4-Hydroxyphenyl]retinamide) in advanced breast cancer and melanoma (1990) (38)
Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar. (1983) (37)
Potent and Selective Double-Headed Thiophene-2-carboximidamide Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma (2014) (37)
Phase I trial of retinol in cancer patients. (1983) (35)
Immunomodulation in humans caused by beta-carotene and vitamin A (1990) (35)
Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol (2008) (35)
Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. (1995) (35)
Prostaglandin A1 and E1 inhibit the plating efficiency and proliferation of murine melanoma cells (Cloudman S-91) in soft agar. (1982) (35)
Vitamin A: a potential inhibitor of human cancer. (1983) (35)
During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. (2004) (34)
Improving breast self-examination compliance: a Southwest Oncology Group randomized trial of three interventions. (1997) (33)
Development of Bowman‐Birk Inhibitor for Chemoprevention of Oral Head and Neck Cancer (2001) (33)
Potential biological explanation of stimulation of colony growth in semi-solid agar by cytotoxic agents. (1983) (32)
A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma (2004) (32)
Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential Mechanisms of Early- and Late-Onset Melanoma (2019) (32)
Modulation of clonogenic human melanoma cells by follicle-stimulating hormone, melatonin, and nerve growth factor. (1981) (32)
A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. (2001) (32)
Actions of melanotropins on mouse melanoma cell growth in vitro. (1986) (32)
Longitudinal Assessment of Air Conduction Audiograms in a Phase III Clinical Trial of Difluoromethylornithine and Sulindac for Prevention of Sporadic Colorectal Adenomas (2008) (32)
Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). (2014) (32)
Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. The Southwest Skin Cancer Prevention Study Group. (1995) (31)
Vitamin A derivatives in the prevention and treatment of human cancer. (1988) (31)
Oral cancer prevention: the case for carotenoids and anti-oxidant nutrients. (1993) (31)
Melanoma: is hair the root of the problem? (2011) (31)
Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. (2010) (31)
Trends in Medical Aid in Dying in Oregon and Washington (2019) (30)
Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck. (1989) (30)
Chromosome alterations in human malignant melanoma. (1989) (30)
Dose-related alpha-difluoromethylornithine ototoxicity. (1991) (29)
Naproxen sodium in treatment of bone pain due to metastatic cancer (1988) (29)
Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. (1999) (28)
Anchorage-independent growth of murine melanoma in serum-less media is dependent on insulin or melanocyte-stimulating hormone. (1985) (28)
Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy (2004) (28)
Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. (1992) (28)
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society , 16 ( 3 ) ISSN 0893-5785 (2003) (26)
Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. (2006) (26)
In vitro modulation of human and murine melanoma growth by prostanoid analogues. (1983) (26)
Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma (2017) (26)
In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. (1982) (26)
Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention. (2009) (25)
Clinical experience with topical tretinoin in the treatment of cervical dysplasia. (1986) (24)
Studies of retinoids in the prevention and treatment of cancer. (1982) (24)
Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. (1984) (23)
Sunshine and skin cancer: a school-based skin cancer prevention project. (1986) (23)
MiTF links Erk1/2 kinase and p21CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells (2010) (22)
Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration. (1989) (22)
Cancer Prevention for Global Health: A Report from the ASPO International Cancer Prevention Interest Group (2012) (22)
Regression of aggressive laryngeal papillomatosis with 13-cis-retinoic acid (accutane). (1986) (22)
How should we move the field of chemopreventive agent development forward in a productive manner? (2005) (21)
Concentration and synthesis of phosphoribosylpyrophosphate in erythrocytes from normal, hyperuricemic, and gouty subjects. (1971) (21)
A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy (2004) (21)
Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial (1988) (21)
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (21)
In vitro retinoid binding and release from a collagen sponge material in a simulated intravaginal environment. (1982) (21)
Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study (2003) (21)
A novel three-dimensional model to quantify metastatic melanoma invasion (2007) (21)
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. (2001) (21)
Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine. (2014) (21)
Chemoprevention of Head and Neck Cancer (2000) (20)
Anti-Cancer Drugs Elicit Re-Expression of UDP-Glucuronosyltransferases in Melanoma Cells (2012) (20)
Topical Delivery of Carvedilol Loaded Nano-Transfersomes for Skin Cancer Chemoprevention (2020) (20)
Differences in basic fibroblast growth factor RNA and protein levels in human primary melanocytes and metastatic melanoma cells. (1992) (20)
Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis (2017) (20)
Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. (1995) (20)
Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. (2001) (19)
The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines (2013) (19)
Thinking about the role (largely ignored) of heavy metals in cancer prevention: hexavalent chromium and melanoma as a case in point. (2011) (19)
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology (2014) (19)
Amyloids, melanins and oxidative stress in melanomagenesis (2015) (19)
Moving a randomized clinical trial into an observational cohort (2013) (18)
Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer. (1992) (18)
Ocular toxic effects of fenretinide. (1990) (18)
Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. (1994) (18)
Strategies for recruitment to a population-based lung cancer prevention trial: the CARET experience with heavy smokers. Beta-Carotene and Retinol Efficacy Trial. (1998) (18)
Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. (2011) (18)
UV or Not UV: Metals Are The Answer (2008) (17)
Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone a interferon and retinoic acid (1986) (17)
Why phase II trials in cervical chemoprevention are negative: what have we learned? (2002) (17)
Biomarker intermediate endpoints and cancer prevention. (1992) (17)
Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. (2001) (17)
HEALTH‐PEERS: A DELIVERY MODEL FOR HEALTH PROMOTION AMONG THE ELDERLY (1987) (17)
Clinical-biologic patterns of metastatic melanoma and their effect on treatment. (1985) (16)
Retinol, vitamins, and cancer prevention: 25 years of learning and relearning. (2008) (16)
Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma. (2009) (16)
Similar self-renewal properties for different sizes of human primary melanoma colonies replated in agar. (1985) (16)
Effect of a-Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer Prevention (1998) (15)
Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers (2003) (15)
Radiation survival of murine and human melanoma cells utilizing two assay systems: monolayer and soft agar. (1988) (15)
Chemoprevention of cancer. (1991) (15)
A quantitatively scored cancer-risk assessment tool: its development and use. (1992) (14)
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? (2010) (14)
Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157) (2004) (14)
A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index (2019) (14)
Role of Vitamin A and Its Derivatives in the Treatment of Human Cancer (1995) (14)
Separation of normal human bone marrow cells by counterflow centrifugal elutriation. I. Morphological analysis and subfractionation of neutrophilic granulocytes. (1979) (14)
Stimulation of human metastatic melanoma colony-forming cells by an acid-sensitive factor in human platelet sonicate. (1985) (14)
An exploratory study of attitudes, beliefs and practices related to the interim dietary guidelines for reducing cancer in the elderly. (1991) (13)
Health-related quality-of-life findings for the prostate cancer prevention trial. (2012) (13)
Back to the Future: Mechanism-Based, Mutation-Specific Combination Chemoprevention with a Synthetic Lethality Approach (2011) (13)
Nutrients and Cancer Prevention (1990) (13)
Chemotherapy of ovarian cancer directed by the human tumor stem cell assay (2004) (13)
Identification and quantitation of intracellular retinol and retinoic acid binding proteins in cultured cells. (1984) (13)
RADIATION SENSITIVITY OF CLONOGENIC HUMAN MELANOMA CELLS (1983) (12)
Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. (2003) (12)
Effect of tumor colony definition on ionizing radiation survival curves of melanoma-colony forming cells. (1987) (12)
Retinoids as anticancer agents. (1993) (12)
Strategies for prevention of cancer in humans. (1992) (12)
Thinking about cancer causality and chemoprevention. (1988) (12)
Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. (2015) (12)
A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. (1986) (12)
A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP (2015) (12)
Criteria for implementation of large and multiagent clinical chemoprevention trials (2000) (12)
Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy. (1990) (12)
A Case-Control Study of the Genetic Variability in Reactive Oxygen Species—Metabolizing Enzymes in Melanoma Risk (2018) (12)
A cancer registry-based analysis on the non-white populations reveals a critical role of the female sex in early-onset melanoma (2018) (11)
Prevention and Treatment of Cancer with Vitamin A and the Retinoids (1984) (11)
Phenothiazine poisoning. A review of 48 cases. (1973) (11)
A community-based feasibility study using wheat bran fiber supplementation to lower colon cancer risk. (1991) (11)
Comparison of calmodulin gene expression in human neonatal melanocytes and metastatic melanoma cell lines. (1992) (10)
Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis. (2014) (10)
Protein kinase Cβ expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate (2005) (10)
A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma. (1988) (10)
In vitro quantification of melanoma tumor cell invasion (1985) (10)
Acceptability, satisfaction and cost of a model-based newsletter for elders in a cancer prevention adherence promotion strategy (1991) (10)
Principles of cancer prevention. (2005) (10)
Cancer prevention in the year 2025: an anticipation. (2000) (10)
Redox-Redux and NADPH Oxidase (NOX): Even More Complicated than We Thought it Might Be. (2017) (9)
Development and characteristics of a human cell assay for screening agents for melanoma prevention (2007) (9)
Hispanics and cancer preventive behavior: the development of a behavioral model and its policy implications. (1989) (9)
Principles of human chemoprevention. (1998) (8)
Chemoprevention of human cancer: a reasonable strategy? (1999) (8)
Diagnostic electron microscopy for amelanotic melanoma: Correlation of patient biopsy, soft agar assay, and xenograft (1983) (8)
Common and distinct mechanisms of different redox‐active carcinogens involved in the transformation of mouse JB6P+ cells (2008) (8)
Cancer Following Total Joint Arthroplasty (2007) (8)
The role of APE/Ref-1 signaling pathway in hepatocellular carcinoma progression (2014) (8)
Dose‐Related α‐Difluoromethylornithine Ototoxicity (1991) (8)
Development of a contingency recruitment plan for a phase III chemoprevention trial of cervical dysplasia. (1990) (8)
Protein kinase C beta expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate. (1993) (7)
Phase II Study of Recombinant α‐Interferon in Malignant Melanoma (1990) (7)
Beta-carotene didn't prevent cancer: what's up doc? (1990) (7)
Human recombinant alpha- and gamma-interferons enhance the cytotoxic properties of tumor necrosis factor on human melanoma. (1988) (7)
A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma (2020) (7)
Can a marker be a surrogate for development of cancer, and would we know it if it exists? (2005) (7)
WHO consensus conference on diet and cancer (2000) (7)
Potential target populations and clinical models for testing chemopreventive agents. (2001) (7)
Predicting risk for the appearance of melanoma. (2006) (7)
Quantitative assessment of cancer risk. (1988) (7)
Cancer population genetics and tumour prevention: an unfulfilled paradigm. (2000) (7)
MiTF links Erk1/2 kinase and p21 activation after UVC radiation in normal human melanocytes and melanoma cells (2010) (7)
Methodological development of dietary fiber intervention to lower colon cancer risk. (1987) (6)
The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. (1989) (6)
Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption. (2021) (6)
Re: Cancer chemoprevention: progress and promise. (1999) (6)
Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas. (2010) (6)
Biological and biochemical properties of a human uveal melanocyte-derived cell line (1980) (6)
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008 (2009) (6)
American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006—Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development (2006) (6)
Pharmacokinetics and Phase I Trial of Retinol and 13-cis-Retinoic Acid (1983) (6)
Biological characterization of an acid-sensitive growth factor from human platelets: role in the proliferation of human melanoma and bovine endothelial cells. (1986) (5)
Cloning efficiency of human melanoma cells is modulated after invasion through a reconstituted basement membrane. (1989) (5)
Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas (2012) (5)
Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (2016) (5)
Nonsurgical treatments for skin cancer: retinoids and alpha-interferon. (1988) (5)
RESTORATION OF ORAL ALL-TRANS RETINOIC ACID BIOAVAILABILITY AFTER A BRIEF DRUG HOLIDAY (1997) (5)
Measuring Redox Status of Melanoma Cells. (2016) (5)
Chemoprevention of human skin cancers. (1991) (5)
Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217) (2014) (5)
Management of human melanoma: what has the last decade wrought? (2003) (5)
Activation of Nuclear Factor-k B in Human Metastatic Melanoma Cells and the Effect of Oxidative Stress 1 (2000) (5)
Solar ultraviolet radiation and skin cancer. A public education program. (1983) (5)
Vitamins and Cancer: Human Cancer Prevention by Vitamins and Micronutrients (1986) (5)
Ornithine decarboxylase (Odc)-1 gene polymorphism effects on baseline tissue polyamine levels and adenoma recurrence in a randomized phase III adenoma prevention trial of DFMO + sulindac versus placebo (2008) (5)
SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. (2012) (5)
Omega-3 fatty acids for aromatase inhibitor–induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927). (2014) (5)
Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned. (2001) (4)
Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. (2016) (4)
Two-photon excited fluorescence spectroscopy and imaging of melanin in vitro and in vivo (2012) (4)
Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. (2017) (4)
WHO consensus conference on diet and cancer. Members of the breast cancer panel. (2000) (4)
Update on in vitro testing on new drugs in ovarian cancer and melanoma. (1981) (4)
A phase II , randomized , controlled trial of S-adenosylmethionine in reducing serum alpha-fetoprotein ( AFP ) in patients with hepatitis C cirrhosis and elevated AFP (2015) (4)
b-Carotene Produces Sustained Remissions in Patients With Oral Leukoplakia (1999) (4)
Chemoprevention of breast cancer. (1992) (4)
Abstract 14: A switch in metabolic phenotype in vemurafenib-resistant melanoma cells to increased amino acid dependence serves as an alternate mechanism for survival (2016) (4)
Biology and Chemosensitivity of Clonogenic, Human Melanoma Tumor Cells (1984) (4)
Phase II trial of bisantrene in patients with metastatic melanoma. (1986) (4)
13-cis-retinoic acid in myelodysplastic syndromes. (1986) (4)
Phase IIA Trial Testing Erlotinib as an Intervention against Intraductal Pancreatic Mucinous Neoplasms (2011) (4)
The human thymus. I. Partial characterization of nonlymphoid cells. (1980) (3)
Chemoprevention of FAP with sulindac (2002) (3)
Screening for cancer: Valuable or not? (2004) (3)
Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia (2004) (3)
Cancer Prevention, Screening, and Early Detection (2008) (3)
Talking to a patient. (2005) (3)
Strategies for Recruitment to a Population-based Lung Cancer Prevention Trial: The CARET Experience with Heavy Smokers I (2008) (3)
Strategy for chemoprevention of human breast cancer. (1988) (3)
Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial (2016) (3)
Targeting melanoma via metal-based stress (2005) (3)
Abstract A21: A Phase IIa trial of metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index (2015) (3)
Melanin oxidation and possible relation to melanosomal abnormalities. (2004) (3)
Isotretinoin for the Treatment of Advanced Human Cancers1 (1985) (3)
Another Negative Chemoprevention Trial: What Can We Learn? (2008) (3)
Abstract CN02-05: Phase IIb randomized clinical chemoprevention trial of a soybean-derived compound (Bowman-Birk inhibitor concentrate) for oral leukoplakia (2010) (3)
Immunohistochemical and ultrastructural study of human melanoma colonies grown in soft agar. (1989) (2)
TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE DEVELOPMENT IN THE POSTNATAL HUMAN THYMUS (1980) (2)
Food Extracts for Chemoprevention: Quo Vadis? (2009) (2)
COMMENT ON: RANDOMIZED TRIAL OF ADJUVANT HUMAN INTERFERON GAMMA VERSUS OBSERVATION IN HIGH-RISK CUTANEOUS MELANOMA : A SOUTHWEST ONCOLOGY GROUP STUDY. AUTHORS' REPLY (1996) (2)
Dexamethasone and zinc in combination inhibit the anchorage-independent growth of S-91 Cloudman murine melanoma. (1985) (2)
Radiosensitivity of murine and human melanoma cells: a comparative study with different models. (1990) (2)
Long-term and residual melanotropin-stimulated tyrosinase activity in S91 melanoma cells is density dependent (1986) (2)
Race, socioeconomic status and survival difference in cutaneous melanoma patients in California. (2006) (2)
Ventral mesencephalic and cortical transplants into the rat striatum display enhanced activity for neutral endopeptidase 24.11 (‘enkephalinase’; CALLA) (1993) (2)
Pulling the trigger. (2004) (2)
Protein Kinase C and Melanocyte Transformation (1988) (2)
Expression of apurinic/apyrymidinic endonuclease/redox effector-1 (APE/Ref-1) is elevated with progression of human melanoma and the therapeutic potential of APE/Ref-1 inhibitors (2005) (2)
Psychosocial Characteristics of Cancer Patients Who Choose Laetrile Therapy (1985) (2)
Evaluation and treatment of the patient with early melanoma. (1995) (2)
Therapeutic prevention of colorectal carcinogenesis (2011) (2)
Pathobiology Clinical Trial of Lovastatin for Various Endpoints of Melanoma A Randomized , Double-Blind , Placebo-Controlled Phase II (2014) (2)
Pro-Oxidant Properties of Melanosomal Melanin from Melanoma Origin (2006) (2)
Scanning and transmission electron microscopic evaluation of human melanoma cells treated with adriamycin and actinomycin D. (1983) (2)
Opportunities for Cancer Epidemiology and Control in Low- and Middle-Income Countries: A Report from the American Society for Preventive Oncology International Cancer Prevention Interest Group (2010) (2)
Retinoids for the management of human cancer: discovered and rediscovered. (1994) (2)
Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS) (2018) (2)
Median effect and long term recovery analysis of biological modifier interactions with difluoromethylornithine on the proliferation of human melanoma cells. (1987) (2)
Improvement of human melanoma colony formation in soft agar using boiled instead of autoclaved agar. (1983) (2)
12‐Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma (2018) (2)
Design and Compliance Considerations of Dietary Intervention Trials (1986) (2)
Studies of human metastatic melanoma colony-forming units (MCFU) in soft agar (1981) (2)
Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (2014) (2)
A randomized placebo-controlled phase III study of duloxetine for treatment of aromatase inhibitor (AI)-associated musculoskeletal symptoms in women with early-stage breast cancer: SWOG S1202. (2014) (2)
Regulation of the redox-sensitive transcription factors NF-kB and AP-1 by ultraviolet light-B in human melanocytes (1996) (1)
Session 7 S21. Chemoprevention of non-melanoma skin cancer: Experience with a polyphenol from green tea (2002) (1)
The place of chemoprevention studies in cancer prevention planning. (1990) (1)
Response of rosiglitazone, UAB 30, and atorvastatin in the human melanoma prevention assayl. (2006) (1)
Chromosome 6 q Involvement in Human Malignant Melanoma (2002) (1)
Clinical Toxicology Pharmacokinetics of 13-Cis-Retinoic Acid Administered Chronically at Low Doses Expected for Cancer Chemoprevention Trials (1986) (1)
A cancer registry-based analysis on the non-white populations reveals a critical role of the female sex in early-onset melanoma (2018) (1)
Replating efficiency of metastatic melanoma cells from lymph node and subcutaneous sites does not predict patient survival (1989) (1)
Management of Stage I cutaneous melanoma. (1983) (1)
Deciphering the Effect of Metformin on Prostate Cancer Risk by Ethnicity (2016) (1)
Abstract Poster session BChromosome alterations in 71 cases of malignant metastatic melanoma (1989) (1)
Radiation survival ofmurine andhumanmelanoma cellsutilizing two assaysystems: Monolayer andsoft agar (1988) (1)
538: The Effect of Difluoromethylornithine on Prostate Size and Polyamines in Men at Familial Risk for Prostate Cancer: Results of a One Year, Randomized, Double Blind, Placebo Controlled Chemoprevention Trial (2007) (1)
Abscopal Outcomes: Reflections on Distant Effects. (2019) (1)
Modulation of Malignant Melanoma Growth with Vitamins and Other Chemically-Defined Biological Modifiers (1984) (1)
Isn't skin cancer preventable? (1992) (1)
Disulfiram facilitates intracellular copper transport that causes Oxidative stress and cell death in human Melanoma cells. (2004) (1)
Redox properties of Melanin: The effect of metal ions and oxygen on synthetic Melanins and Melanoma in culture. (2004) (1)
Adherence enhancers in pill-related clinical trials: a health behavior in cancer prevention model-based approach. (1996) (1)
Luteinizing hormone modulates human melanoma tumor stem cell expression and binds to human melanoma cells (1981) (1)
180. Expression of the retinoic acid receptors and effect of retinoic acid on human primary neonatal melanocytes and metastatic melanoma cells strains (1992) (1)
Prevention of cervical intraepithelial neoplasia and cervical (1995) (1)
Chemoprevention of head and neck cancer (2000) (1)
Abstract 1179: Unique metabolic profile of Vemurafenib-resistant melanoma cells: a quantitative proteomics approach (2015) (1)
Etiologic pathogenesis of Melanoma: A Unifying hypothesis for missing attributable risk and implications for Chemoprevention. (2004) (1)
155 – Redox Rebalance Mediated by Nrf2 and Nox1 after UV Radiation in Human Melanoma Development (2014) (1)
A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci of the Colorectum (2015) (1)
Control of Human Preneoplasia with Retinoids and Other Compounds (1990) (1)
Dietary Fiber or Piroxicam as Potential Cancer Prevention Agents: Effects on Rectal Epithelial Cell Proliferation in Humans at Increased Risk of Colon Cancer (1990) (1)
Abstract 2552: Loss of MiTF sensitizes melanoma cells to chemotherapy due in part to reduced LAMP1 accumulation (2010) (1)
CONFERENCE - PREVENTION OF HUMAN CANCER - INTRODUCTION (1989) (1)
Molecular cancer prevention: Phase IIa trial of Erlotinib for IPMNs and the prevention of pancreatic cancer. (2006) (1)
Methods for evaluating the morphological and immunohistochemical properties of human tumor colonies grown in soft agar (1982) (1)
Cobalt and copper are candidates as co-carcinogens in the pathogenesis of cutaneous melanoma (2007) (1)
Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete? (2000) (1)
Nrf2 Mediates Chemoresistance in Melanoma (2011) (1)
Individualized patient chemotherapy: use of a human tumor colony formation technique. (1982) (1)
RelA , p 50 and Inhibitor of kappa B alpha are Elevated in Human Metastatic Melanoma Cells and Respond Aberrantly to Ultraviolet (2001) (1)
Synergistic interactions of disulfiram, BSO and arsenic trioxide on drug resistant melanoma cell lines. (2006) (1)
Role of Retinoids in Prevention of Cutaneous Cancer (2018) (1)
Oregon's Death With Dignity Act-Reply. (2018) (1)
The risk of cancer and serum vitamin A and E and carotenoids. (1984) (1)
S27. Prevention of colorectal polyps by DMFO and Sulindac (2008) (0)
Abstract B82: Two factors contribute to negative results of a phase-IIB chemoprevention trial of Bowman-Birk inhibitor concentrate on oral leukoplakia (2011) (0)
Rural Coalition Meeting (1994) (0)
Experience with Retinoids as Prevention and Treatment for Human Cancers (1986) (0)
Stimulationof HumanMetastatic MelanomaColony-formingCells by an Acid-sensitiveFactor in HumanPlateletSonicate1 (1985) (0)
Development of a human Melanoma prevention assay. (2004) (0)
Risk Factor Models and Personalized Health: Opportunities and Challenges for Asymptomatic Individuals (2015) (0)
S39. Toxicity and long-term problems with Aspirin and NSAID's: The problem (2008) (0)
A Randomized, Double Blind, Phase III Trial Using Oral (cid:1) -Carotene Supplementation for Women with High-Grade Cervical Intraepithelial Neoplasia 1 (2001) (0)
Biology of human melanoma colony-forming cells. (1988) (0)
Chemoprevention Breast Cancer Workshop, November 20, 1987 Panel Discussions (1988) (0)
Chemoprevention of Cervical Cancer (2004) (0)
WALKING WITH A STICK (2006) (0)
Abstract A137: NO initiates progression of human melanoma via a feedback loop mediated by APE/Ref-1, new opportunities for chemoprevention. (2008) (0)
Identification and quantitation of intracellular retinol and retinoic acid binding proteins in cultured cells. - eScholarship (1984) (0)
The human thymus. II. Partial characterization of thymocytes separated on bovine serum albumin gradients. (1980) (0)
UC Irvine UC Irvine Previously Published Works Title Chemoprevention of head and neck cancer (0)
POETRY BY CANCER CAREGIVERS (2003) (0)
Possible mechanisms and rankings for agents screened in the Human Cell Melanoma Prevention Assay. (2006) (0)
Title Another negative chemoprevention trial : What can we learn ? (2007) (0)
chemoprevention of breast and colon cancer (2000) (0)
Chemoprevention of breast and colon cancer. - eScholarship (2000) (0)
Disulfiram induces apoptosis of melanoma cells by altering glutathione REDOX status and mitochondrial membrane potential (2001) (0)
When Y our F avorite P atient R elapses: P hysician G rief a nd Well-Being i n t he P ractice o f O ncology (2003) (0)
In Vitro Phase II Trial of Vinca Alkaloids1 (1981) (0)
Neuronal Nitric Oxide Synthase (nNOS)/NO, An Accelerator of Melanoma Progression, is a Potential Target for Chemoprevention (2011) (0)
Abstract 1937: APE/Ref-1, a drugable target for the therapy of human melanoma (2012) (0)
Correction--malignant glioma. (1997) (0)
Development of new transformants of mouse JB6P series cells as tools for understanding redox and transcriptional factor regulation (2007) (0)
Abstract 2735: Diagnosis of prostate cancer without tumor cells using differentially expressed genes in the tumor microenvironment (2010) (0)
Lyase, Feedback, Biochemical, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Melanoma, Models, Biological, Neoplasm Metastasis, Nitric Oxide, Stilbenes, Transcription Factor AP-1 (2008) (0)
Comparison of assays used for in vitro chemosensitivity testing of human tumours. (1984) (0)
Faculty Opinions recommendation of Neonatal exposure to UVR alters skin immune system development, and suppresses immunity in adulthood. (2011) (0)
Re: Vitamin A Analogue for Breast Cancer Prevention: a Grade of F or Incomplete? (2000) (0)
384 binding sites for 125I-human luteinizing hormone (hLH) on murine and human melanoma cells (1983) (0)
CHEMOPREVENTION AND SCREENING OF PROSTATE AND BREAST CANCERS - -- - - - - - - I 231N I Major Issues In chemopreve11tion of prostate and breast cancer. (2017) (0)
Tumor virus and human cancer. (1981) (0)
Abstract SY26-02: SWOG S0701 phase III randomized trial of three antibiotic regimens to eradicate helicobacter pylori: efficacy and failure at one year (2012) (0)
The Effectiveness of Chemoprevention Agents Is Underestimated When Lesion Sizes Are Rounded (2010) (0)
S7 Thinking about the role (largely ignored) of heavy metals in cancer prevention: chromium and melanoma as a case in point (2010) (0)
Faculty of 1000 evaluation for Phenolic compounds from plants as nitric oxide production inhibitors. (2011) (0)
Faculty Opinions recommendation of Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis. (2011) (0)
Genes in Stroma Diagnosis of Prostate Cancer Using Differentially Expressed (2011) (0)
Title Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer : SWOG S 9630 (2016) (0)
Point/Counterpoint Point: Surrogate End Point Biomarkers Are Likely To Be Limited in Their Usefulness in the Development of Cancer Chemoprevention Agents against Sporadic Cancers 1 (2003) (0)
Future Strategies for Cancer Prevention Trials (2021) (0)
Faculty of 1000 evaluation for Modelling melanoma in mice. (2012) (0)
Title Page / Contents / Preface (1983) (0)
Abstract 2906: Curcumin reduces aberrant crypt foci (ACF) number but does not alter prostaglandin E2 (PGE2) or 5-hydroxyeicosanopentaneic acid (5-HETE) concentration in ACF or in normal human colorectal mucosa (2010) (0)
Rethinking medical oncology training and education. (1988) (0)
CYTOGENETICS OF HUMAN MELANOMA RECURRJNG SITES OF CHROMOSOME CHANGE IN MALIGNANT MELANOMA (2017) (0)
Incorporation of DOPA by amelanotic melanoma cells: A comparison of data from patient biopsy, soft bilayer agar assay, and xenograft (1982) (0)
Abstract ED08-01: How should we optimize technology to allow personalized medicine? (2008) (0)
Title The role of APE / Ref-1 signaling pathway in hepatocellular carcinoma progression (2014) (0)
The Influence of Randomized Controlled Cancer Chemoprevention Trials on the Evolution of Regulatory Assessments (2011) (0)
Abstract 2399: System analysis of adapted and quiescent/dormancy(QD) models of drug resistance in melanoma cell lines (2016) (0)
ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN (2018) (0)
Title Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial Permalink (0)
Clinical Studies of Vitamin A and Its Synthetic Derivatives in Cancer Prevention and Treatment at the University of Arizona1 (1983) (0)
APE/Ref-1, a druggable target for the therapy of human melanoma (2011) (0)
SHORT COMMUNICATION Chromosome 6q Involvement in Human Malignant Melanoma (2002) (0)
Tetrazolium staining by optical scanning overestimates colony size and number of colonies counted. (1987) (0)
Abstract 2418: NADPH Oxidase 1 over-expression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells (2012) (0)
Clinical Trials Report (2001) (0)
EFFECI- OF TUMOR COLONY DEFINITION ON IONIZING RADIATION SURVIVAL CURVES OF MELANOMA-COLONY FORMING CELLS (2003) (0)
Differential expression of NFkB and response to oxidative stress in normal human melanocytes and metastatic melanoma cells (1998) (0)
Endocrine therapy of breast cancer: a new look. The role of receptor assays. (1977) (0)
Retinoids as anticancer agents. (1988) (0)
Abnormalities of protein kinase C (PKC)-β and retinoic acid receptor (RAR)-β expression during human melanocyte progression to melanoma: 87 (1993) (0)
Aching for Tomorrow (2007) (0)
activation after UVC radiation in normal human melanocytes and melanoma cells (2010) (0)
Protein synthesis and the growth kinetics of ehrlich ascites tumor. Abstr. (1969) (0)
Characterization of NADPH Oxidase Gene Family Expression in Human Melanocytes and Melanoma Cell Lines (2010) (0)
929 INCOMPLETE LYMPHOCYTE DIFFERENTIATION IN B CELL LINES FROM IMMUNODEFICIENT PATIENTS (1981) (0)
With Dignity (2008) (0)
INVITRO CHEMOSENSITIVITIES OF HUMAN-TUMOR STEM-CELLS TO THE PHASE-II DRUG 4'-(9- ACRIDINYLAMINO)METHANESULFON-M-ANISIDIDE AND PROSPECTIVE INVIVO CORRELATIONS (2006) (0)
A potential mitochondrial survival mechanism in human metastatic melanoma cells (2006) (0)
Usage of Oregon's Death With Dignity Act (DWDA). (2016) (0)
12 - Cu-Based Drugs in Combination Therapy for Melanoma (2013) (0)
Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. - eScholarship (2007) (0)
Pulsed Electromagnetic Fields do Not Reduce Vesicant Skin Ulcers in Mice (1986) (0)
Predicting risk for the appearance of melanoma. - eScholarship (2006) (0)
Abstract PR-01: Properties of adenomas in subjects treated with difluoromethylornithine and sulindac for reduction of colorectal adenomas (2011) (0)
Dietary intakes and tissue concentrations of polyamines in a colon cancer chemoprevention clinical trial. (2006) (0)
Vitamin a and its derivatives: the retinoids. (1985) (0)
Utilization of N-acetyl putrescine by human melanoma cells in vitro for growth in the pr sence of difluoremethylornithine (DFMO) (1987) (0)
Diagnosis and treatment of carcinoma, based on the genotype of ODC1 (2010) (0)
Erk 1 / 2 kinase and p 21 CIP 1 / WAF 1 activation after UVC radiation in normal human melanocytes and melanoma cells (2010) (0)
Abstract B26: Analyzing health benefits beyond the treatment period (2008) (0)
S-ADENOSYLMETHIONINE STABILIZES DUAL-SPECI- FICITY MAPK PHOSPHATASE PROTEIN (DUSP1) BY INHIBITING PROTEASOMAL ACTIVITY: IMPLICATION IN THE PATHOGENESIS AND CHEMOPREVENTION OF HEPATOCELLULAR CARCINOMA (2015) (0)
The ÃŸ-Caroteneand Retinol Efficacy Trial (CARET) for Chemoprevention of Lung Cancer in High Risk Populations: Smokers and Asbestos-exposed Workers1 (2006) (0)
System Analysis of the Molecular Characteristics of the Adapted and Quiescent/Dormancy(QD) State in an in Vitro Model for Late Relapse of Metastatic Melanoma (2016) (0)
Protein kinase C 13 expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate (2005) (0)
Pharmacokinetics and phase I clinical trial of retinol (R) in cancer patients (1982) (0)
Double Discordance in the ROS-induction and Anti-tumor activity of Luteolin, a Classical Free Radical Scavenger (2017) (0)
Effect of single dose ionizing radiation on the cellular proliferation and apparent radiosensitivity of melanoma. (1990) (0)
Coping with end-of-life stress (EOLS): Poetry as a therapeutic communication intervention. (2019) (0)
Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas (2012) (0)
Abstract CN07-01: A phase IIa randomized, double-blind trial of erlotinib in inhibiting EGF receptor signaling in aberrant crypt foci of the colon (2013) (0)
804 Marked Efficacy of Difluoromethylornithine (DFMO) Plus Sulindac in Reducing Recurrent Colorectal Adenomas in Patients with Prior Adenomas: Results of a Randomized, Placebo-Controlled Double-Blind Trial (2008) (0)
A phase IIa clinical biomarker trial of aspirin and dietary arginine restriction in colorectal cancer patients. (2011) (0)
What do redox metabolism, printers/lithographers, and hip replacements have to do with the prevention of melanoma? (2007) (0)
Treatment and Prevention of Intraepithelial Neoplasia : An Important Target for Accelerated New Agent Development Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia 1 (2002) (0)
Abstract LB-142: Marked efficacy of difluoromethylornithine plus sulindac in reducing recurrent colorectal adenomas in patients with prior adenomas: Results of a randomized, placebo-controlled, double-blind Phase III trial. (2008) (0)
Modulation of Human Solid Tumor Colony Forming Units by Retinoids1 (1983) (0)
Role of obesity in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. (2011) (0)
Clinical Investigation Phase Trial of fl-AII-trans-Retinoic Acid for Cervical Intraepithelial Neoplasia Delivered via a Collagen Sponge and Cervical Cap (2005) (0)
Antioxidants and redox-active metals in the epigenetic pathogenesis of cutaneous melanoma: epidemiologic and experimental evidence (2008) (0)
Session 4 Problems and promise of surrogate markers in tumor prevention (2004) (0)
S6. The scientific basis of chemoprevention in humans: What's important? (2008) (0)
Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells. (2016) (0)
Concluding Remarks: Future Perspectives (1983) (0)
Replace the advance directive with a patient activation approach to serious illness communication (2022) (0)
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for VariousEndpoints ofMelanoma Pathobiology (2014) (0)
Colorectal Neoplasia Phase IIa Clinical Trial of Curcumin for the Prevention of Updated (2011) (0)
Pneumococcal antibodies in older tobacco smokers indicate naturally acquired immuntiy (1996) (0)
Title Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients Permalink (0)
Abstract A29: Rectal mucosal polyamine and PGE2 levels and risk of colorectal adenomas in a phase IIb/III trial of combination difluoromethylornithine (DFMO) plus sulindac (2010) (0)
Abstract A67: Phase IIA trial testing erlotinib as an intervention against intraductal papillary mucinous neoplasms (2010) (0)
Trends inMedical Aid in Dying in Oregon andWashington (2019) (0)
Cytogenetic analysis of 9 new human melanoma cell lines: Further evidence for involvement of chromosome 6 alterations (1987) (0)
Abstract A9: UDP-glucuronosyltransferase 2B7 (UGT2B7) inhibits melanoma invasiveness (2010) (0)
Reversal of BRAF Resistance via Re-Establishment of Redox Balance Using a Unique Anti-Oxidant Strategy (2014) (0)
2160 DIAGNOSIS OF PROSTATE CANCER WITHOUT TUMOR CELLS USING DIFFERENTIALLY EXPRESSED GENES IN THE TUMOR MICROENVIRONMENT (2010) (0)
ROS-independent inhibition of melanoma tumor growth by luteolin involves BRAF and the MAPK pathway (2018) (0)
Solar ultraviolet radiation and skin cancer. A public education program. (1982) (0)
Preclinical investigation of DNA histone deacetylase inhibition in ovarian cancer (2017) (0)
A phase II, randomized, controlled trial of the safety and efficacy of S-adenosyl-L-methionine disulphate p-toluene-sulfonate (SAMe) in reducing serum alpha-fetoprotein (AFP) in patients with hepatitis C and moderately elevated AFP. (2006) (0)
Functional role for the UDP-glucuronosyltransferases (UGTs) in melanoma drug resistance (2011) (0)
Neutral melanoma transforming growth factor (NMSA) a novel human platelet protein (1986) (0)
The ionophore thiomaltol induces rapid lysosomal accumulation of copper and apoptosis in melanoma. (2021) (0)
Involvement of heavy metal ions in the pathogenesis of cutaneous melanoma: experimental and epidemiologic evidence (2007) (0)
Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention (2023) (0)
Gender difference in the association of melanoma etiology to solar UV exposure. (2015) (0)
UC Irvine UC Irvine Previously Published Works Title New perspectives on melanoma pathogenesis and chemoprevention (0)
Title INVITRO MODULATION OF HUMAN AND MURINE MELANOMA GROWTH BY PROSTANOID ANALOGS Permalink (2002) (0)
Abstract 2823: PHA-739358, a pan-Aurora kinase inhibitor, induces apoptosis and inhibits invasion in melanoma cell lines (2012) (0)
Abstract 268: Regulation of the UDP-glucuronosyltransferases (UGTs) by UV exposure in human melanocytes (2012) (0)
A Randomized, Double-Blind, Placebo-Controlled Phase II ClinicalTrialofLovastatinforVariousEndpointsofMelanoma Pathobiology (2014) (0)
Abstract 5466: nNOS, a novel target for melanoma prevention and therapy (2010) (0)
What to Do With the Participants/Patients in Phase III Clinical Cancer Trials That Have Been Stopped by the FDA. (2016) (0)
Abstract 3247: SAMe versus placebo for the reduction of serum AFP in patients with hepatitis C cirrhosis and moderately elevated AFP: A randomized, placebo-controlled, double-blind phase II trial (2014) (0)
Major issues in chemoprevention of prostate and breast cancer (2017) (0)
Human papillomavirus infection and number of lifetime sexual partners are strong predictors for natural regression of cervical intraepithelial neoplasia 2 and 3 (2002) (0)
PATHOGENESIS AND CHEMOPREVENTION (2006) (0)
Terminal deoxynucleotidyl transferase activity in thymus biopsies of immunodeficient patients. (1982) (0)
Abstract 2553: Characterization of the UDP-Glucuronosyltransferases in melanocytes and melanoma (2010) (0)
Effect of (cid:97) -Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer Prevention (1998) (0)
Effects of combination chemoprevention on markers of cell turnover and agent action in colorectal mucosal tissue from patients in a Phase III trial of difluoromethylornithine and sulindac for prevention of colon polyp recurrence (2007) (0)
OT2-07-02: SWOG S0927: A Randomized Double Blind Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor (AI)-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer. (2011) (0)
A phase II study of o~-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma (2004) (0)
80. Induction of tumor suppression/cell senescence in human melanoma cells following transfection of protein kinase C βII gene (1992) (0)
Evolution of Cancer Prevention and Control Program at the Arizona Cancer Center. (1988) (0)
Cytogenetic comparison of multiple lesions from three patients with metastatic malignant melanoma (1989) (0)
Abstract 1286: Pharmacodynamics of oral curcumin in plasma and rectal mucosa in a Phase IIa trial (2011) (0)
Vitamin A and Cancer (1984) (0)

This paper list is powered by the following services:

Other Resources About Frank L. Meyskens Jr.

What Schools Are Affiliated With Frank L. Meyskens Jr.?

Frank L. Meyskens Jr. is affiliated with the following schools: